CY1109955T1 - Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion - Google Patents

Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion

Info

Publication number
CY1109955T1
CY1109955T1 CY20101100273T CY101100273T CY1109955T1 CY 1109955 T1 CY1109955 T1 CY 1109955T1 CY 20101100273 T CY20101100273 T CY 20101100273T CY 101100273 T CY101100273 T CY 101100273T CY 1109955 T1 CY1109955 T1 CY 1109955T1
Authority
CY
Cyprus
Prior art keywords
bupropion
hydrochlorine
modified
modified label
wellbutrin
Prior art date
Application number
CY20101100273T
Other languages
English (en)
Inventor
Werner Oberegger
Okpo Eradiri
Fang Zhou
Paul Maes
Original Assignee
Biovail Laboratories International Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34192557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109955(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Laboratories International Srl filed Critical Biovail Laboratories International Srl
Publication of CY1109955T1 publication Critical patent/CY1109955T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ένα δισκίο τροποποιημένης απελευθέρωσης υδροχλωριούχου bupropion που περιλαμβάνει (i) έναν πυρήνα που περιλαμβάνει μία ενεργό ποσότητα υδροχλωριούχου bupropion, έναν προσδέτη, ένα λιπαντικό· και (ii) μία επικάλυψη ελεγχόμενης απελευθέρωσης που περιβάλλει τον εν λόγω πυρήνα· και (iii) ένα φράγμα υγρασίας που περιβάλλει την εν λόγω επικάλυψη ελεγχόμενης απελευθέρωσης, όπου το δισκίο τροποποιημένης απελευθέρωσης είναι βιοϊσοδύναμο με τα δισκία Wellbutrin® ή Zyban®/Wellbutrin®SR.
CY20101100273T 2003-08-08 2010-03-22 Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion CY1109955T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03818223A EP1575565B1 (en) 2003-08-08 2003-08-08 Modified-release tablet of bupropion hydrochloride
PCT/US2003/024700 WO2005016318A1 (en) 2003-08-08 2003-08-08 Modified-release tablet of bupropion hydrochloride

Publications (1)

Publication Number Publication Date
CY1109955T1 true CY1109955T1 (el) 2014-09-10

Family

ID=34192557

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100273T CY1109955T1 (el) 2003-08-08 2010-03-22 Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion

Country Status (30)

Country Link
US (2) US20050238718A1 (el)
EP (1) EP1575565B1 (el)
JP (1) JP2007521231A (el)
KR (1) KR101087464B1 (el)
CN (1) CN1819821B (el)
AP (1) AP1899A (el)
AT (1) ATE454138T1 (el)
AU (1) AU2003264002B2 (el)
BR (1) BRPI0318456B8 (el)
CA (1) CA2524300C (el)
CR (1) CR8056A (el)
CY (1) CY1109955T1 (el)
DE (1) DE60330909D1 (el)
DK (1) DK1575565T3 (el)
EA (1) EA013737B1 (el)
ES (1) ES2336913T3 (el)
HK (1) HK1083193A1 (el)
HR (1) HRP20050625B1 (el)
IL (1) IL171870A (el)
IS (1) IS2779B (el)
ME (2) ME00391B (el)
MX (1) MXPA05012637A (el)
NO (2) NO335271B1 (el)
NZ (1) NZ544281A (el)
PL (1) PL196544B1 (el)
PT (1) PT1575565E (el)
RS (2) RS20060132A (el)
SI (1) SI1575565T1 (el)
TN (1) TNSN06016A1 (el)
WO (1) WO2005016318A1 (el)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
DK1799196T3 (en) 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
US7645802B2 (en) * 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
PT1954241E (pt) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Formulação de zonisamida de libertação sustentada
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20100008987A1 (en) * 2006-08-21 2010-01-14 Pasula Basavaiah Chowdary Modified Release Pharmaceutical Composition of Bupropion Hydrochloride
CA2667228C (en) 2006-10-23 2015-07-14 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
ATE460925T1 (de) 2006-11-09 2010-04-15 Orexigen Therapeutics Inc Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
WO2008148013A1 (en) * 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
US20100203128A1 (en) * 2007-08-07 2010-08-12 Biovail Laboratories International Srl Bupropion hydrobromide and therapeutic applications
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
CA2721832C (en) 2008-04-17 2018-08-07 Micell Technologies, Inc. Stents having bioabsorbable layers
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US20120076865A1 (en) * 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2858640B1 (en) 2012-06-06 2020-03-25 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
WO2014165264A1 (en) 2013-03-12 2014-10-09 Micell Technologies, Inc. Bioabsorbable biomedical implants
KR102079613B1 (ko) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
SG11202008056SA (en) * 2018-02-23 2020-09-29 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12083080B2 (en) 2023-12-04 2024-09-10 Richard Louis Price Therapeutic methods using bupropion hydrobromide

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
US3885048A (en) * 1971-02-08 1975-05-20 James J Liggett Method for preparing simulated meat, fish and dairy products
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
DK62184D0 (da) 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5082655A (en) 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
DE3672652D1 (de) 1985-03-29 1990-08-23 Shinko Electric Co Ltd Eisenbahnfahrzeug mit linearmotor.
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
IT1191674B (it) 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4880622A (en) 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CH668553A5 (de) 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4837980A (en) 1987-07-01 1989-06-13 The Uniroyal Goodrich Tire Company Method and apparatus for tire uniformity correction
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4795641A (en) 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5187150A (en) 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
JPH02257309A (ja) 1989-03-30 1990-10-18 Fanuc Ltd Ｎｃプログラムの描画方法
US5030457A (en) 1989-08-28 1991-07-09 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
GB2245559A (en) 1990-06-25 1992-01-08 Farmos Oy Bioceramic system for delivery of a bioactive compound.
EP0542926B1 (en) 1990-08-07 1995-02-15 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DE69327050T2 (de) 1992-04-15 2000-02-24 Sri International, Menlo Park Reinigung von 5-7-dien-steroiden von einem steringemisch
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
DE59309257D1 (de) 1992-10-26 1999-02-11 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung von mikrokapseln
WO1994012159A1 (en) 1992-11-30 1994-06-09 Pfizer Inc. Supported liquid membrane delivery devices
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5535556A (en) 1994-04-18 1996-07-16 Hughes, Jr.; John P. Basement wall construction
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US6020002A (en) 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5478572A (en) 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5762961A (en) 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
EP0888111B1 (en) 1996-03-08 2003-05-21 Nycomed Danmark A/S Modified release multiple-units dosage composition
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
FR2747921B1 (fr) 1996-04-24 1998-10-30 Adir Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
SI9600330A (sl) * 1996-11-11 1998-06-30 KEKO VARICON d.o.o. Zaščitna komponenta z več funkcijami
WO1998030208A1 (en) 1997-01-10 1998-07-16 Abbott Laboratories Tablet for the controlled release of active agents
US6168873B1 (en) 1997-05-29 2001-01-02 Canon Kabushiki Kaisha Electrode substrate and recording medium
AU7706598A (en) 1997-05-30 1998-12-30 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
IL152330A0 (en) 1997-07-01 2003-05-29 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
AU750808B2 (en) 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6221917B1 (en) 1997-12-30 2001-04-24 American Home Products Corporation Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5919484A (en) 1998-01-15 1999-07-06 Isp Investments Inc. Controlled release, drug-delivery tableted composition including a polymer of a vinyl amide, (meth)acrylic acid, a long chain alkyl (meth)acrylate and a lower alkyl (meth)acrylate
CA2318921A1 (en) 1998-01-29 1999-08-05 John R. Mccullough Pharmacological uses of optically pure (+)-bupropion
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
US6117452A (en) 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
US6129931A (en) 1998-09-03 2000-10-10 Isp Investments Inc. Controlled-release, drug-delivery tableted composition including a complex between poly(maleic diacid-alkyl vinyl ether) and polyvinylpyrrolidone
PT1121104E (pt) * 1998-10-01 2005-05-31 Novartis Ag Novas formulacoes orais de libertacao controlada
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
ES2213404T3 (es) 1998-12-17 2004-08-16 Alza Corporation Transformacion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples revestimientos.
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6589553B2 (en) * 2001-02-08 2003-07-08 Andrx Pharmaceuticals, Inc. Controlled release oral dosage form
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU3895400A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Control of metabolism
FR2791809B1 (fr) 1999-04-01 2001-06-15 Air Liquide Procede et dispositif de traitement d'articles stockes dans des conteneurs et appareil de stockage dote d'un tel dispositif
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6387403B1 (en) 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6306436B1 (en) * 2000-04-28 2001-10-23 Teva Pharmaceuticals Usa, Inc. Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
US6541532B1 (en) 2000-06-02 2003-04-01 Milliken & Company Scorch inhibiting compositions for polyurethane foams
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
JP4969761B2 (ja) * 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
US6491947B2 (en) 2000-11-03 2002-12-10 Chemlink Laboratories, Llc Expanded perborate salt, use, and method of production
CN1352938A (zh) * 2000-11-14 2002-06-12 北京万全阳光医药科技有限公司 盐酸安非他酮缓释片
US6960357B2 (en) * 2001-05-25 2005-11-01 Mistral Pharma Inc. Chemical delivery device
ITMI20011457A1 (it) * 2001-07-09 2003-01-09 Valpharma Sa Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
BR0215262A (pt) * 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
ES2285088T3 (es) * 2002-01-09 2007-11-16 Ucb Farchim S.A. Composiciones farmaceuticas de liberacion modificada.
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
SI1476138T1 (sl) * 2002-02-21 2012-07-31 Valeant Internat Barbados Srl Formulacije s prirejenim sproščanjem vsaj ene oblike tramadola
KR100483588B1 (ko) * 2002-07-11 2005-04-18 주식회사 하이닉스반도체 난드형 플래시 메모리 소자의 셀렉트 라인 형성 방법
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004087175A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates

Also Published As

Publication number Publication date
BR0318456A (pt) 2006-09-12
ES2336913T3 (es) 2010-04-19
RS20060132A (en) 2008-06-05
TNSN06016A1 (en) 2007-10-03
MEP3608A (en) 2011-05-10
BRPI0318456B8 (pt) 2021-05-25
AU2003264002A1 (en) 2005-03-07
CN1819821B (zh) 2010-10-13
NO335271B1 (no) 2014-10-27
NO20053245D0 (no) 2005-07-01
DK1575565T3 (da) 2010-04-12
CR8056A (es) 2008-07-29
US7537784B2 (en) 2009-05-26
HRP20050625A2 (en) 2008-07-31
DE60330909D1 (de) 2010-02-25
EP1575565B1 (en) 2010-01-06
AP1899A (en) 2008-10-10
BRPI0318456B1 (pt) 2021-01-05
EA013737B1 (ru) 2010-06-30
MXPA05012637A (es) 2006-02-24
RS51934B (en) 2012-02-29
SI1575565T1 (sl) 2010-04-30
HK1083193A1 (en) 2006-06-30
KR101087464B1 (ko) 2011-11-25
IL171870A (en) 2011-08-31
KR20060071392A (ko) 2006-06-26
IS2779B (is) 2012-05-15
PL378539A1 (pl) 2006-02-06
NZ544281A (en) 2008-07-31
EP1575565A1 (en) 2005-09-21
EA200600206A1 (ru) 2006-06-30
CN1819821A (zh) 2006-08-16
PL196544B1 (pl) 2008-01-31
NO20053245L (no) 2005-10-04
US20060228415A1 (en) 2006-10-12
PT1575565E (pt) 2010-03-03
IS7930A (is) 2005-07-01
AU2003264002B2 (en) 2010-09-02
CA2524300A1 (en) 2005-02-24
ATE454138T1 (de) 2010-01-15
ME00391B (me) 2011-10-10
EP1575565A4 (en) 2007-05-02
WO2005016318A1 (en) 2005-02-24
NO2015003I1 (no) 2015-02-16
HRP20050625B1 (hr) 2015-08-28
JP2007521231A (ja) 2007-08-02
AP2005003463A0 (en) 2005-12-31
US20050238718A1 (en) 2005-10-27
CA2524300C (en) 2008-10-28

Similar Documents

Publication Publication Date Title
CY1109955T1 (el) Δισκιο τροποποιημενης απελευθερωσης υδροχλωριουχου bupropion
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
BR0106100B1 (pt) composição de gesso fixado, artigo, e, método para preparar uma composição de gesso fixado.
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
BR0103034B1 (pt) bomba.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
ECSP056216A (es) Tableta de liberación modificada del clorhidrato de bupropion
ES1050531Y (es) Estructura para falsos techos.
IT1313589B1 (it) Composizioni a rilascio controllato di paracetamolo.
MY145995A (en) Modified-release tablet of bupropion hydrochloride
ES1049603Y (es) Caja-envase para objetos pequeños.
ECSP003609A (es) Derivados de 2- dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
ES1045098Y (es) Tope perfeccionado para soportes omega.
ES1048877Y (es) Tetilla para biberon.
ES1049353Y (es) Brandilla guarda-cuerpos para edificios.
ECSP993045A (es) Derivados de acridina, procedimiento para su preparacion y su utilizacion como analgesico
ECSP003570A (es) Derivados de 2- bencil-3-dimetilamino-1-fenil- propano
ES1045622Y (es) Sobre para regalo.
ES1058646Y (es) Banda envolvente termica que incorpora corrientes de electroestimulacion, con aplicacion simultanea o independiente de ambos sistemas.
GT200500342A (es) Tableta de liberacion modificada del clorhidrato de bupropion
ITRE20020099A1 (it) Dispenser per piccoli oggetti come pastiglie e simili.
UY26523A1 (es) Derivados de aminometil-fenil-ciclohexanona, procedimiento para su preparación, el uso de los derivados de aminometil-fenil-ciclohexanona para la preparación de medicamentos que contienen los derivados de aminometil-fenil-ciclohexanona
ES1047119Y (es) Maquina para el despiece de cefalopodos.